Scarica l'app Stockscreener
456.84
0.79%
3.56
Dopo l'orario di chiusura:
456.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$453.28
Aprire:
$450.31
Volume 24 ore:
610.68K
Relative Volume:
0.84
Capitalizzazione di mercato:
$20.61B
Reddito:
$3.08B
Utile/perdita netta:
$1.24B
Rapporto P/E:
17.84
EPS:
25.6108
Flusso di cassa netto:
$1.07B
1 W Prestazione:
+8.98%
1M Prestazione:
+14.06%
6M Prestazione:
+56.60%
1 anno Prestazione:
+30.58%
Intervallo 1D:
$449.51
$459.48
Intervallo di 1 settimana:
$419.21
$459.48
Portata 52W:
$266.98
$459.48
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Confronta UTHR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
456.84 | 20.50B | 3.08B | 1.24B | 1.07B | 25.61 |
|
ZTS
Zoetis Inc
|
142.77 | 64.42B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.46 | 45.95B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
8.82 | 39.14B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.07 | 22.90B | 16.70B | -157.13M | 1.19B | -0.1446 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
Is There Still an Opportunity in United Therapeutics After Its 25.8% Year to Date Surge? - simplywall.st
How Positive TETON-2 Results for Tyvaso Have Changed United Therapeutics' (UTHR) Investment Story - simplywall.st
News impact scoring models applied to United Therapeutics CorporationPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
United Therapeutics stock hits all-time high at 442.02 USD - Investing.com
United Therapeutics stock hits all-time high at 442.02 USD By Investing.com - Investing.com South Africa
TD Cowen maintains Buy rating on United Therapeutics stock, citing IPF opportunity - Investing.com
Jefferies reiterates Buy rating on United Therapeutics stock amid patent case - Investing.com
UBS maintains United Therapeutics stock Buy rating amid patent litigation By Investing.com - Investing.com Canada
United Therapeutics COO sells $9.49m in UTHR stock By Investing.com - Investing.com South Africa
United Therapeutics COO sells $9.49m in UTHR stock - Investing.com India
Is IPF the Next Big Market Opportunity for United Therapeutics? - Yahoo Finance
UBS maintains United Therapeutics stock Buy rating amid patent litigation - Investing.com India
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
United Therapeutics stock price target raised to $580 by UBS on Tyvaso outlook - Investing.com Australia
United Therapeutics Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments - Investing.com Australia
United Therapeutics (UTHR): UBS Raises Price Target to $580, Mai - GuruFocus
United Therapeutics stock maintains Buy rating at H.C. Wainwright amid patent case developments By Investing.com - Investing.com Australia
Will United Therapeutics Corporation (UTH) stock beat international competitionWeekly Trade Review & Reliable Trade Execution Plans - newser.com
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data - Investing.com Canada
United Therapeutics stock holds Buy rating at TD Cowen on strong IPF data By Investing.com - Investing.com South Africa
United Therapeutics Corporation $UTHR Holdings Lifted by State of Alaska Department of Revenue - MarketBeat
Why United Therapeutics Corporation (UTH) stock stays undervaluedTrade Ideas & Verified Chart Pattern Trade Signals - newser.com
Analyzing drawdowns of United Therapeutics Corporation with statistical tools2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Why United Therapeutics Corporation (UTH) stock gets analyst attention2025 Winners & Losers & Low Risk Investment Opportunities - newser.com
Chart based analysis of United Therapeutics Corporation trendsInsider Selling & Real-Time Stock Movement Alerts - newser.com
Augustine Asset Management Inc. Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
United Therapeutics Rides Tyvaso Wins To Major Gains - Finimize
RBC Capital initiates United Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
RBC Capital Initiates Coverage on United Therapeutics (UTHR) wit - GuruFocus
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Sowell Financial Services LLC Invests $333,000 in United Therapeutics Corporation $UTHR - MarketBeat
RBC Capital initiates United Therapeutics stock with Outperform rating - Investing.com
Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Rothblatt, United Therapeutics CEO, sells $3.4m in UTHR stock By Investing.com - Investing.com Nigeria
Insider Sell: Christopher Causey Sells 1,000 Shares of United Th - GuruFocus
Rothblatt, United Therapeutics CEO, sells $3.4m in UTHR stock - Investing.com India
United Therapeutics Corp. Hits New 52-Week High of $442.01 - Markets Mojo
United Therapeutics Corporation $UTHR Shares Sold by Ruffer LLP - MarketBeat
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.55%
1.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):